Alife Launches New AI Platform to Optimize IVF

Alife Health announced the launch of its Alife Assist™ platform today. This new suite of products aims to help fertility clinics utilize and leverage data-driven insights and artificial intelligence (AI) to optimize and support clinical decision-making during critical stages of the in-vitro fertilization (IVF) process, as well as streamline overall clinic operations. This marks the company’s official entry into the clinical market after conducting two years of research and development with its notable list of clinic partners, advisors, and investors.

“I founded Alife because I knew that AI has the potential to drastically impact the IVF process. Yet, as we began to work with fertility clinics around the country, we quickly identified a parallel opportunity for improvement: the need for a central platform to digitize clinic workflow and support collective decision-making. Our team is thrilled to launch Alife Assist™, a first-of-its-kind product suite that optimizes the IVF process from end-to-end,” says Paxton Maeder-York, CEO of Alife. “Together, our products will help clinics harness the power of AI and advanced analytics to streamline their workflow and bring a more personalized experience to their patients.”

“AI has enormous potential to help inform our decisions as clinicians. When it comes to patient care decision making, the more data and information, the better. If we can harness the knowledge of thousands of past patient cycles from clinics around the world, we can make more informed choices about the patient sitting right in front of us,” says Louis Weckstein, MD.

The Alife Assist™platform is made up of three robust products that are supported by the team’s scientific research and collaboration with top clinics:

  • Stim Assist™ is a set of AI-powered clinical decision support tools that helps reproductive endocrinologists choose the optimal medication dose and timing to maximize the number of mature eggs retrieved from an ovarian stimulation cycle. These tools use one of the largest and most diverse IVF datasets in the world which contains millions of rows of historical data from previous patient cycles to provide insights on what treatment has worked best for similar patients. Alife’s research indicates that in general more mature oocytes are associated with a higher live birth percentage
  • Embryo Assist™ streamlines and enhances an embryologist’s workflow in a single tool to keep consistent records, save time, and automate reports. This enables embryologists to digitally capture, grade, organize, and report embryo grading data like never before, all with real-time EMR connection.
  • Insights™ is an analytics dashboard that gives directors, managers, and administrators the ability to monitor and visualize their clinic’s performance in real-time. This simplifies the process of extracting trends and sharing reports to optimize overall clinic operations.

Alife Assist™ is now available for IVF clinics in the United States.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”